Overall venture funding, as well as “first financing” rounds, fell significantly in the second quarter, reversing 2025’s fast ...

The Kiteworks research reveals that 27% of life organizations acknowledge that more than 30% of their AI-processed data contains sensitive or private information. In pharmaceutical contexts, this ...

International companies are increasingly inking licensing deals with Chinese biotechs as concerns regarding drug pricing and ...

The chief financial officer and a manager of a failed digital pharmacy company must defend against some federal regulator ...

An AI healthcare platform analyzed 13 years of FDA data to identify companies with highest recall rates and most dangerous ...

Amgen has transitioned into a mature, cash-generating pharma-biotech hybrid. Click here to find out why AMGN stock is a Buy.

A Sun Pharmaceutical plant in India that has been repeatedly cited by the FDA for serious quality control issues failed another inspection last month.

In this week's "Adam's Biotech Scorecard," Adam also looks at a new trend: the Wall Street-to-pharma career arc.

53 biotech leaders urge FDA not to restrict mifepristone access over 'fatally flawed' report By Darren Incorvaia Jul 2, 2025 2:14pm mifepristone Food and Drug Administration (FDA) abortion Martin ...

A potential $4 billion licensing deal with Vor Bio triggered a slide in RemeGen's stock price. Otsuka obtained a BCMAXCD3 bispecific from Harbour BioMed to develop against autoimmune diseases. | A ...

One of the biggest barriers to the adoption of any new biotechnology tool is validation and regulatory clarity.